15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Receives Authorization From the UK Regulatory Agency to Conduct a Phase 2 Clinical Trial for COVI-DROPS in an Outpatient Setting
June 11, 2021 16:11 ET | Sorrento Therapeutics, Inc.
Large Phase 2 efficacy trial cleared to start in the United Kingdom in newly diagnosed SARS-CoV-2 infected patients.COVI-DROPS is administered by intranasal drops and the antibody is active against...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Announces Clinical Research Agreement With Mayo Clinic and FDA Clearance for the First Phase 1b Pilot Study Using Sofusa Lymphatic Drug Delivery Technology to Deliver Ipilimumab in Patients With Melanoma
June 11, 2021 09:00 ET | Sorrento Therapeutics, Inc.
SAN DIEGO, June 11, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced a research collaboration agreement with Mayo Clinic to conduct human clinical...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Announces Positive Results From Its License Partner, Kelun, on a Phase I Study of Safety and Pharmacokinetics of A166, a Novel HER2 ADC for Advanced HER2 Positive Breast Cancers
June 04, 2021 15:13 ET | Sorrento Therapeutics, Inc.
A166 (ASCO Abstract #1024) is a third generation antibody drug conjugate (ADC) against HER2-positive breast cancer with Levena’s proprietary tubulin inhibitor Duo-5 toxin, cleavable linker and...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer (DAR-NK) Cells With The Vision to Bring “Off-The-Shelf" NK Cell-Based Cancer Treatments Rapidly to Patients
June 04, 2021 13:00 ET | Sorrento Therapeutics, Inc.
SAN DIEGO and STOCKHOLM, Sweden, June 04, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the Company has entered into an additional...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Completes Acquisition of ACEA Therapeutics, Creating a Major Oncology Franchise
June 02, 2021 09:00 ET | Sorrento Therapeutics, Inc.
AMONG MULTIPLE CLINICAL- AND PRECLINICAL-STAGE NCE (NEW CHEMICAL ENTITY) COMPOUNDS ACQUIRED, ABIVERTINIB IS AN ANCHORING LATE-STAGE DRUG PRODUCT WITH POSITIVE CLINICAL TRIAL RESULTS IN BOTH NON-SMALL...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Announces Addition of COVI-STIX™ (Covid-19 Virus Rapid Antigen Detection Test) to the Official Mexican Government List of Emergency Use Approved Point of Care Rapid Antigen Tests
June 02, 2021 07:00 ET | Sorrento Therapeutics, Inc.
COVI-STIX has been added to the official government list of point of care rapid antigen tests useful for the detection of SARS-CoV-2 in Mexico...
Agencia Nacional de Vigilancia Sanitaria (ANVISA) autoriza ensayo clínico principal fase II de COVI-MSC™ de Sorrento en pacientes hospitalizados con síndrome de dificultad respiratoria aguda con COVID-19
May 20, 2021 15:38 ET | Sorrento Therapeutics, Inc.
Ensayo clínico principal fase II de COVI-MSC ahora autorizado para proceder en Brasil.El estudio compara la terapia con células madre mesenquimales con placebo (y atención estándar) en 100 pacientes...
Agência Nacional de Vigilância Sanitária (ANVISA) autoriza Fase 2 Sorrento do Ensaio Clínico Principal de COVI-MSC™ em Pacientes Hospitalizados com Síndrome do Distúrbio Respiratório Agudo com COVID-19
May 20, 2021 15:38 ET | Sorrento Therapeutics, Inc.
A Fase 2 do Ensaio Clínico Principal de COVI-MSC agora está autorizado a prosseguir.O estudo irá comparar a terapia usando células-tronco mesenquimais no placebo (e tratamento padrão) em 100 pacientes...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Pivotal Clinical Trial of COVI-MSC™ in Hospitalized COVID-19 Patients With Acute Respiratory Distress Syndrome
May 20, 2021 09:00 ET | Sorrento Therapeutics, Inc.
Brazil Phase 2 Pivotal clinical trial of COVI-MSC is now authorized to proceed.The study will compare therapy using mesenchymal stem cells to placebo (and standard of care) in 100 COVID-19 patients...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Reports Positive Initial Result in Dosing of First Enbrel-Non-Responding Rheumatoid Arthritis Patient With the Sofusa® Lymphatic Drug Delivery Device
May 19, 2021 21:30 ET | Sorrento Therapeutics, Inc.
Sofusa is a drug delivery platform technology which delivers biologic therapies through the skin directly into the lymphatic system with potential to improve efficacy and safety and reduce the...